Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs

Zinger Key Points
  • JNJ reaffirms 2024 reported sales guidance of $88 billion-$88.4 billion versus consensus of $88.74 billion.
  • The company's cancer cell therapy, Carvykti, generated sales of $186 million, up around 60% year over year.

On Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70.

The pharma giant reported sales of $22.45 billion, up 4.3% year-over-year, beating the consensus of $22.31 billion.

Operational growth was 6.6%, and adjusted operational growth was 6.5%. The adjusted operational growth excluding COVID-19 Vaccine was 7.1%.

Also Read: Johnson & Johnson Faces MedTech Challenges But Is ‘On Track’ To Meet 2024 Guidance: Goldman Sachs.

Innovative Medicine sales increased to $14.49 billion, up 5.5% (+8% adjusted operational). Growth was driven by Darzalex (daratumumab), Erleada (apalutamide), Tremfya (guselkumab), Stelara (ustekinumab), and Spravato (esketamine).

Stelara sales rose 3.1% to $2.89 billion. Darzalex sales rose 18.4% to $2.88 billion. The company’s cancer cell therapy, Carvykti, generated sales of $186 million, up around 60% year over year.

MedTech sales increased 2.2% (+4%) to $7.96 billion, driven primarily by electrophysiology products and Abiomed in Cardiovascular, previously referred to as Interventional Solutions, and wound closure products in General Surgery.

“With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and continued expansion of newly launched products, including ACUVUE OASYS MAX 1-Day contact lenses and our VARIPULSE platform, we have a strong foundation for near and long-term growth,” said Joaquin Duato, Chairman and CEO.

Guidance: Johnson & Johnson raises fiscal year 2024 operational sales guidance to $89.2 billion-$89.6 billion versus prior guidance of $88.7 billion-$89.1 billion.

JNJ reaffirms 2024 reported sales guidance of $88 billion-$88.4 billion versus consensus of $88.74 billion.

The company expects fiscal year 2024 adjusted EPS guidance of $9.97–$10.07, down from prior guidance of $10.57–$10.72 versus the consensus of $10.01, to reflect the impact of recent acquisitions of Shockwave Medical, Proteologix, and NM26 Bispecific Antibody.

Price Action: JNJ shares are up 0.12% at $151.20 during the premarket session at the last check on Wednesday.

Read Next:

Photo via Wikimedia Commons

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefsStories That Matter
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!